Plain-English translation of NCT05746039 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Obesity research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This is a small, early-stage research study testing whether semaglutide—a medication already used to help people lose weight—can be safely used in people who have both obesity and serious lung conditions like pulmonary hypertension, chronic obstructive pulmonary disease, or interstitial lung disease. The study will follow 8 participants over 12 weeks to see if the medication is tolerable, how well people stick with it, and whether it affects their physical function and body composition.
People with advanced lung disease and excess weight face unique challenges, because extra weight can make breathing more difficult and worsen lung function. Currently, there is limited information about whether this medication is safe and effective for this specific group of patients, so researchers want to explore whether it could be a helpful treatment option.
You likely qualify if…
You likely don't qualify if…
You would receive one injection of the medication under your skin once per week for 12 weeks. Before starting and after the 12-week treatment period, you would complete tests to measure your lung function, physical ability, and body composition (fat and muscle). The research team would monitor you throughout the study to watch for any side effects and to see how well you tolerate the medication.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
United States